Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals
Terminated
University Hospital, Basel, Switzerland
Phase 4
2015-07-01
The purpose of this study is to assess whether a boosting by cobicistat results in similar
concentrations of darunavir in the brain compared to a boosting by ritonavir.
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
Completed
Radboud University
Phase 1
2015-11-01
This study aims to provide the evidence that 150mg of cobicistat will have the same effect on
the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with
atazanavir 300mg.
The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e.
AUC) is increased when osimertinib is co-administered with cobicistat in patients with
relatively low plasma trough concentration while receiving the standard osimertinib dose.
ZonMw: The Netherlands Organisation for Health Research and Development
Early Phase 1
2020-11-01
The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e.
AUC) is increased when osimertinib is co-administered with cobicistat in patients with
relatively low plasma trough concentration while receiving the standard osimertinib dose.
The main objective of this study is to evaluate if systemic exposure of osimertinib (i.e.
AUC) is increased when osimertinib is co-administered with cobicistat in patients with
relatively low plasma trough concentration while receiving the standard osimertinib dose.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
